#Davita jones
Explore tagged Tumblr posts
ladiesofaau · 2 years ago
Text
Tumblr media Tumblr media
DAVITA ⤷ All American , 5.18 "This is How We Do It"
26 notes · View notes
missbangtangirl · 11 months ago
Text
Tumblr media Tumblr media Tumblr media
6 notes · View notes
fmarkets · 1 year ago
Text
$COIN #SP500 #NASDAQ #SPX $CEL-USD
Date: November 13, 2023 Today, the financial markets witnessed a downward trend, largely influenced by a series of earnings reports and industry performances. The Dow Jones Industrial Average (DJIA) closed down -2.63%, the SandP 500 fell -2.19%, and the Nasdaq Composite dropped -1.87%. Leading the decline were several major companies across various sectors. Coinbase Global Inc (COIN) experienced a -3.73% drop, followed closely by V F Corporation (VFC) at -3.49%, Sony Group Corporation (SONY) at -3.33%, Chewy Inc (CHWY) at -2.61%, Caesars Entertainment Inc (CZR) at -2.54%, Micron Technology Inc (MU) at -2.19%, and Eli Lilly And Company (LLY) at -2.15%. In earnings news, Tyson Foods Inc, Emerson Electric Co, Harmony Gold Mining Company Limited, Tennessee Valley Authority, and Franklin Resources Inc released their reports. Despite these announcements, the best trading stocks remained Davita Inc (DVA) with a growth of 7.02%, Insulet Corporation (PODD) at 4.95%, Henry Schein Inc (HSIC) with a gain of 4.40% https://csimarket.com/news/news_markets.php?date=2023-11-13T14505&utm_source=dlvr.it&utm_medium=tumblr
0 notes
perry-tannenbaum · 5 years ago
Text
Trying an Offramp on the Highway to Prison
Trying an Offramp on the Highway to Prison
Review: Pipeline by Three Bone Theatre By Perry Tannenbaum
Tumblr media
  One of 25 winners of the MacArthur Foundation’s “Genius Grant” last year, playwright Dominique Morisseau has begun, somewhat belatedly, a stealth invasion of the Queen City. How stealthy? UNC Charlotte and Three Bone Theatre, the first two outfits to present Morisseau works here, both latched onto the same acclaimed Detroit ‘67for…
View On WordPress
0 notes
dermontag · 3 years ago
Photo
Tumblr media
Flucht in Staatsanleihen Ukraine-Krise lässt Wall Street zittern 11.02.2022, 22:46 Uhr Der drohende Krieg in der Ukraine macht an der Wall Street viele Anleger nervös. Hinzu kommt der starke Preisauftrieb in den USA. Gefragt sind bei den Investoren daher sichere Häfen wie Staatsanleihen. Die US-Börsen sind im späteren Handelsverlauf kräftig abgesackt. Anleger flüchteten vor allem wegen des sich zuspitzenden Ukraine-Konflikts aus risikoreichen Aktien in als sicher empfundene Häfen wie Staatsanleihen oder Währungen wie den Yen und den US-Dollar. S&P 500 4.414,97 Für zusätzliche Nervosität sorgt außerdem nach wie vor der starke Preisauftrieb in den USA. Seitdem am Donnerstag die höchste Inflationsrate seit gut 40 Jahren veröffentlicht wurde, spekulieren Marktteilnehmer umso fieberhafter über anstehende Zinsschritte, da diese womöglich rascher und umfangreicher erfolgen könnten als bisher erwartet. Der Dow Jones Industrial büßte 1,43 Prozent auf 34 738,06 Punkte ein. Während es angesichts des zunächst freundlichen Handelsauftakts noch nach einem Wochenplus für den Wall-Street-Index ausgesehen hatte, verbuchte er letztlich ein Minus von einem Prozent. Der den breiten Markt abdeckende Index S&P 500 beendete den Tag 1,90 Prozent tiefer auf 4418,64 Punkten. Der Technologie-Index Nasdaq 100 sackte um 3,07 Prozent auf 14 253,84 Punkte ab, was im Wochenverlauf einen Verlust von drei Prozent bedeutet. Eigentlich sei mit einer gewissen Beruhigung der Lage in der Ukraine gerechnet worden, "aber das scheint nicht mehr der Fall zu sein", kommentierte Marktanalyst Edward Moya vom Broker Oanda. Nach Berichten darüber, dass die Vereinigten Staaten von einer fortgesetzten Invasion in die Ukraine ausgingen, hätten Aktienhändler schnell die Verkaufsknöpfe gedrückt. Under Armour 15,39 Wie der Nationale US-Sicherheitsberater Jake Sullivan kurz darauf sagte, befinde man sich aktuell "in einem Zeitfenster, in dem eine Invasion jederzeit beginnen könnte, sollte sich (der russische Präsident) Wladimir Putin dazu entschließen, sie anzuordnen". Da die US-Regierung einen Einmarsch noch vor dem Ende der Olympischen Winterspiele am Sonntag nächster Woche für möglich hält, werden nun rund 3000 weitere US-Streitkräfte in den Osten Europas geschickt. Under Armour sackt ab Unternehmensnachrichten waren vor dem Wochenende etwas dünner gesät. Der Sportartikelhersteller Under Armour verschreckte die Anleger mit seinen Geschäftszahlen. Die Aktie sackte um mehr als elf Prozent ab, der Nike-Konkurrent litt im Weihnachtsquartal unter rückläufigen Ergebnissen. Das angehobene Umsatzziel für das laufende Quartal konnte vor diesem Hintergrund nicht beruhigen. Expedia 169,94 Die Anteile von Expedia drehten nach einem Rekordhoch von knapp 210,50 US-Dollar ins Minus und büßten 2,7 Prozent ein. Der jüngste Zwischenbericht des Online-Reiseunternehmens war allerdings stark ausgefallen: Trotz der Pandemie gelang dem Unternehmen der Sprung zurück in die Gewinnzone. Die britische Bank Barclays und ihre schweizerische Konkurrentin Credit Suisse hoben daraufhin ihre Kursziele für die Aktie an und bestätigten ihre Kaufempfehlungen. Seit Jahresbeginn steht bereits ein Kursplus von rund sieben Prozent zu Buche - der Nasdaq 100 verlor im selben Zeitraum indes fast 13 Prozent. Die Davita-Aktien gaben ihre Tagesgewinne ebenfalls ab, retteten jedoch ein Plus von 0,1 Prozent im schwachen Gesamtmarkt. Der Dialyse-Spezialist übertraf mit seinem Ergebnis- und Umsatzanstieg im vergangenen Quartal die Analystenschätzungen. Euro / US-Dollar 1,14 Der Euro sackte unter die Marke von 1,14 Dollar und kostete zum Börsenschluss an der Wall Street 1,1341 Dollar. Die Europäische Zentralbank setzte den Referenzkurs zuvor auf 1,1417 (Donnerstag: 1,1439) Dollar fest. Der Dollar kostete damit 0,8759 (0,8742) Euro. Am US-Rentenmarkt schnellte der Terminkontrakt für zehnjährige Treasuries (T-Note-Future) um 0,65 Prozent auf 126,61 Punkte hoch. Die Rendite für zehnjährige Staatspapiere sank auf 1,92 Prozent. Am Vortag war sie mit bis zu 2,05 Prozent auf den höchsten Stand seit gut zweieinhalb Jahren gestiegen.
0 notes
emrys-girlwithasaber · 6 years ago
Text
The 20 questions tag
Thanks for the tag @lilyevansreyjakuu I’ll do my best. <3 
Rules: answer the 20 questions below and tag 20 bloggers that you want to get to know better.
I tag anyone who wants to do this. If you are reading this and want to share, tag....you’re it. ;) Just tag me because I would like to read it. :) 
Nickname: Smoke, Anne with an E (from Anne of Green Gables), really too many to mention. LOL
Zodiac: I have no idea. LOL
Height: 5 ‘8"
Time: 4:35 p.m.
Nationality: American 
Language: English (can read and speak Middle English), some Spanish
Favorite band/artist: pretty much every 70s classic rock band, 80′s pop, U2, John Williams, Patrick Doyle, Thomas Newman, Alan Silvestri, Hans Zimmer, Coldplay, Norah Jones, Joshua Bell, Emmylou Harris, Alison Krauss, Merry Ellen Kirk, Chris Pile,  Josh Groban, Coldplay, Emmy Rossum (Sentimental Journey album), Hayley Westenra, David Mead, Johnny Cash, Andrew Lloyd Webber, Nathan Gunn, Loreena McKennitt, Byrne and Kelly, Adele, Coldplay, Meav
Books: Jane Eyre, Pride and Prejudice, Persuasion, Pendragon Cycle by Stephen R. Lawhead, The Lord of the Rings, Chronicles of Narnia (especially The Silver Chair), Till We Have Faces by C.S. Lewis, Shadow Children Sequence by Haddix, The Chosen by Chaim Potok, My Name is Asher Lev by Chaim Potok, Davita’s Harp by  Chaim Potok, Confessions of An Ugly Stepsister by G Maguire, Sacred Romance by Elridge
Movies/ shows / novelas/ YouTuber: Star Wars, Lord of the Rings, Master and Commander, Endeavour, Sherlock, Poldark, Doctor Who, Little Dorrit, Pride and Prejudice (1995), Sense and Sensibility, Wives and Daughters, Horatio Hornblower, The Avengers, Captain America (all three), Thor (all three), Gilmore Girls, Anne of Green Gables, Road to Avonlea, Meet Me in St. Louis, Gigi, Sleeping Beauty, Henry V, Much Ado About Nothing and basically anything by Pixar.  Safiya Nygaard, The Den of Nerds, My Nerd World hosted by Jon Justice, Lindsey Ellis,  Zabrena, HGTV Homemade, 
Fruit: Watermelon, Apples, Oranges
Color: RED! (my favorite: always has been, always will be) Black, white, dark tones of green and blue.
What I’m wearing: leggings and purple tank top
Favorite thing to do: draw, write, edit, have deep meaningful discussions, watch movies, going to theater productions, concerts, and art shows
Description: shy , funny (sometimes), idealistic, passionate, healer, 
Random things I do: everything about me is random...LOL
Pretty much that is all everyone .
Tags : 
Source: the-moonlily
2 notes · View notes
perfectirishgifts · 4 years ago
Text
Top Stocks To Buy Today As Jobless Claims Improve And Markets Rise
New Post has been published on https://perfectirishgifts.com/top-stocks-to-buy-today-as-jobless-claims-improve-and-markets-rise-2/
Top Stocks To Buy Today As Jobless Claims Improve And Markets Rise
Markets rose on Thursday after jobless claims from last week came in at much better than expected figures. Jobless claims fell for the first time in three weeks, and came in at 712,000- beating a consensus estimate of 780,00. Meanwhile, investors continue to wait for Friday when the Labor Department releases its November jobs report. The U.S. economy is expected to add 440,000 jobs while the unemployment rate is estimated to decrease to 6.7%. After the U.K. on Wednesday and became the first country to grant emergency approval to Pfizer and BioNTech’s Covid-19 vaccine, vaccine-related sentiment also helped markets as well. This vaccine, as well as Moderna’s vaccine, continue to stand by for emergency FDA approval in America. The Dow Jones climbed 130 points, led by a 5% surge in Boeing. The S&P 500 rose 0.3% after hitting a second consecutive record closing high in the previous session. The Nasdaq also gained .6% and hit another intraday record high. For investors looking to make the most of this market, the deep learning algorithms at Q.ai have crunched the data to give you a set of Top Buys. Our Artificial Intelligence (“AI”) systems assessed each firm on parameters of Technicals, Growth, Low Volatility Momentum, and Quality Value to find the best long plays.
Sign up for the free Forbes AI Investor newsletter here to join an exclusive AI investing community and get premium investing ideas before markets open.
Davita Inc (DVA)
Our first Top Buy for today is Davita Inc. Davita is a healthcare company that provides kidney dialysis services through a network of 2,753 outpatient dialysis centers in the United States serving 206,900 patients. Davita also owns and operates 259 outpatient dialysis centers in 10 other countries serving 28,700 patients. Our AI systems rated the company C in Technicals, C in Growth, A in Low Volatility Momentum, and A in Quality Value. The stock closed down 0.21% to $108.36 on volume of 772,299 vs its 10-day price average of $109.18 and its 22-day price average of $105.76, and is up 44.0% for the year. Revenue grew by 1.36% in the last fiscal year and grew by 6.07% over the last three fiscal years, Operating Income grew by 2.4% in the last fiscal year and grew by 10.17% over the last three fiscal years, EPS grew by 26.74% in the last fiscal year and grew by 92.49% over the last three fiscal years. Revenue was $11388.48M in the last fiscal year compared to $10883.67M three years ago, Operating Income was $1755.53M in the last fiscal year compared to $1631.68M three years ago, EPS was $5.27 in the last fiscal year compared to $3.47 three years ago, and ROE was 21.47% in the last year compared to 18.36% three years ago. Forward 12M Revenue is expected to grow by 0.99% over the next 12 months, and the stock is trading with a Forward 12M P/E of 13.5.
MORE FROM FORBESDaVita (DVA)
Simple Moving Average of Davita Inc
Kennedy-Wilson Holdings Inc (KW)
Our second Top Buy for today is Kennedy-Wilson Holdings. Kennedy-Wilson is Kennedy Wilson is a global real estate investment company focused on multifamily and office properties located in the Western U.S., U.K., and Ireland. Our AI systems rated the company A in Technicals, A in Growth, B in Low Volatility Momentum, and C in Quality Value. The stock closed down 1.05% to $16.08 on volume of 391,580 vs its 10-day price average of $16.4 and its 22-day price average of $15.5, and is down 25.14% for the year. Revenue was $641.5M in the last fiscal year compared to $827.0M three years ago, Operating Income was $41.7M in the last fiscal year, compared to $56.2M three years ago, EPS was $1.58 in the last fiscal year compared to $0.83 three years ago, and ROE was 20.38% in the last year compared to 7.04% three years ago.
MORE FROM FORBESKennedy-Wilson Holdings (KW)
Simple Moving Average of Kennedy-Wilson Holdings Inc
Altria Group Inc (MO)
One of the world’s largest producers and marketers of tobacco, cigarettes and related products is our next Top Buy today- Altria Group. Our AI systems rated Altria C in Technicals, C in Growth, B in Low Volatility Momentum, and A in Quality Value. The stock closed down 1.16% to $40.02 on volume of 8,985,294 vs its 10-day price average of $40.25 and its 22-day price average of $39.5, and is down 13.13% for the year. Revenue grew by 4.0% in the last fiscal year and grew by 5.61% over the last three fiscal years, Operating Income grew by 7.17% in the last fiscal year and grew by 16.3% over the last three fiscal years, and EPS grew by -154.9% in the last fiscal year. Revenue was $19796.0M in the last fiscal year compared to $19494.0M three years ago, Operating Income was $10810.0M in the last fiscal year compared to $9961.0M three years ago, EPS was $(0.7) in the last fiscal year compared to $5.31 three years ago, and ROE was (12.25%) in the last year compared to 72.46% three years ago. Forward 12M Revenue is expected to grow by 1.39% over the next 12 months, and the stock is trading with a Forward 12M P/E of 8.88.
MORE FROM FORBESAltria Group (MO)
Simple Moving Average of Altria Group Inc
Primerica Inc (PRI)
Georgia-based Primerica Inc is our fourth Top Buy today. Primerica is a multi-level marketing company that sells insurance and financial services. Our AI systems rated Primerica A in Technicals, C in Growth, A in Low Volatility Momentum, and B in Quality Value. The stock closed up 0.28% to $133.78 on volume of 115,622 vs its 10-day price average of $132.34 and its 22-day price average of $126.69, and is up 2.79% for the year. Revenue grew by 5.03% in the last fiscal year and grew by 28.59% over the last three fiscal years, Operating Income grew by 4.91% in the last fiscal year and grew by 33.7% over the last three fiscal years, EPS grew by 7.75% in the last fiscal year and grew by 22.03% over the last three fiscal years. Revenue was $2100.83M in the last fiscal year compared to $1715.97M three years ago, Operating Income was $554.25M in the last fiscal year compared to $434.87M three years ago, EPS was $8.62 in the last fiscal year compared to $7.61 three years ago, and ROE was 23.53% in the last year compared to 26.53% three years ago. Forward 12M Revenue is expected to grow by 7.23% over the next 12 months, and the stock is trading with a Forward 12M P/E of 12.82.
MORE FROM FORBESPrimerica (PRI)
Simple Moving Average of Primerica Inc
Tegna Inc (TGNA)
Our final Top Buy today is Tegna Inc. Tegna is a broadcast, digital media and marketing services company that owns or operates 66 television stations in 54 markets, and holds properties in digital media. Our AI systems rated Tegna B in Technicals, B in Growth, A in Low Volatility Momentum, and A in Quality Value. The stock closed up 0.83% to $14.62 on volume of 1,236,930 vs its 10-day price average of $14.49 and its 22-day price average of $13.99, and is down 9.14% for the year. Revenue grew by 17.16% in the last fiscal year and grew by 41.57% over the last three fiscal years, Operating Income grew by 13.12% in the last fiscal year and grew by 23.44% over the last three fiscal years, and EPS grew by 11.43% in the last fiscal year and grew by 15.95% over the last three fiscal years. Revenue was $2299.5M in the last fiscal year compared to $1903.03M three years ago, Operating Income was $593.24M in the last fiscal year compared to $543.65M three years ago, EPS was $1.31 in the last fiscal year, and compared to $1.26 three years ago, and ROE was 19.53% in the last year compared to 24.93% three years ago. Forward 12M Revenue is expected to grow by 0.32% over the next 12 months, and the stock is trading with a Forward 12M P/E of 6.87.
MORE FROM FORBESTEGNA (TGNA)
Simple Moving Average of Tegna Inc
Liked what you read? Sign up for our free Forbes AI Investor Newsletter here to get AI driven investing ideas weekly. For a limited time, subscribers can join an exclusive slack group to get these ideas before markets open.
More from Investing in Perfectirishgifts
0 notes
missbangtangirl · 2 years ago
Text
Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media
4 notes · View notes
page58-blog1 · 7 years ago
Text
Life, Love & Sex. Three Best Friends are Living Their Best Lives in New Web Series 'Leimert Park' (Trailer)
Life, Love & Sex. Three Best Friends are Living Their Best Lives in New Web Series ‘Leimert Park’ (Trailer)
    “He’s going to be working with us for a while.” Set against a vibrant but rapidly gentrifying ‘Leimert Park,’ the web-series follows best friends and roommates as they navigate life, love and sex. Things get complicated when three best friends share a house in South LA’s Leimert Park. Despite being married, beats-maker Mickey hasn’t had an orgasm in three months, Bridget mistakes sex for love…
View On WordPress
0 notes
wutbju · 4 years ago
Photo
Tumblr media
Gary L. Fries, 74, of Lenox Township, PA, died Thursday, September 10, 2020 at Allied Services Skilled Nursing Center, Scranton, PA. His wife of 50 years is the former Grace Jenkins.
Born February 22, 1946 in Carbondale, PA, he was the son of the late Edwin Arthur Fries and the late Doris Esther Ross Fries Jenkin. He was also preceded in death by his step father, Thomas Jenkin, II. Gary was raised by his mom and two late uncles, Lucious "Junior" Ross and Clarence Ross.
Gary was a graduate of East Benton High School and attended Bob Jones University, Greenville, SC, for music. He had operated a dairy and chicken farm and later worked for Sandvik Steel, Precision International, PennDot and retired from Clarks Distribution.
Gary was a member of the Lenoxville United Methodist Church, where he sang in the choir and was also a member of the Lenoxville Band. He was a multi-talented musician having a natural ability to play just about any instrument but was gifted at the banjo, accordion and piano. He was an avid outdoorsman who enjoyed hunting and fishing, was an avid gun collector and a member of the NRA. Gary was a classic car and motorcycle enthusiast and a fan of everything country western.
A special thank you is extended to the nurses and staff at DaVita Dialysis, Eynon, and home health care nurses, Rachel and Dolly for their loving care and support.
He is survived by three children: Jeremy Fries and wife, Christina of Laceyville, PA, Jessica Munley and husband, Jason of Jessup, PA and Jennifer Canfield and husband, Kevin of Lenox Township, PA; nine grandchildren: Mason, Micah, Jason, Jesse, Jackie, Jordan, Nicolas, Kathleen and Lily; three sisters-in-law: Phyllis Jenkins, Carol Demian and Kristen Reynolds; a brother-in-law: Paul Jenkins; several nieces and nephews; and his faithful companions: Della and Olga.
He was also preceded in death by two infant sons: Jonathan and James.
A visitation was held Monday, September 14, 2020 from 5 to 7 p.m. from the Shifler-Parise Funeral Home and Cremation Services, 18 Airport Road, Clifford, PA. A funeral service was conducted at 7:00 p.m. by Levi Ransom. To honor Gary the family asked that those were able, wear their favorite western boots, hat, flannel or western shirt.
In lieu of flowers, memorial contributions were made to The Seeing Eye, Inc., P.O. Box 375, Morristown, NJ 07963 or https://www.seeingeye.org/
0 notes
thecapitaladvisor · 5 years ago
Text
Warren Buffett: História e Estratégia de Investimentos
Quem é Warren Buffett, como ficou rico, onde investe e qual sua estratégia de investimento? Descubra e saiba como investir na bolsa de valores da forma como os investidores de sucesso fazem! Uma das formas para ganhar dinheiro com os investimentos é modelar a mentalidade dos grandes investidores de sucesso da bolsa e replicar os seus acertos. A maioria deles se tornaram bilionários, mesmo começando a investir na bolsa de valores com pouco dinheiro. Se você deseja alcançar a sua independência financeira, a melhor forma é saber como investir na bolsa de valores com sucesso. “Em investimentos, o que é confortável raramente é rentável.” Robert Arnott, CEO da Research Affiliates. Então, você está pronto para saber quem é Warren Buffett e conhecer suas estratégias de investimentos? Leia até o final e descubra agora como investir melhor o seu dinheiro.
Quem é Warren Buffett?
Warren Buffett é investidor, filantropo e o principal acionista, presidente do conselho e diretor executivo da Berkshire Hathaway. Considerado um dos investidores mais importantes do mercado financeiro, Warren Buffett acumula uma fortuna estimada em quase US$ 90 bilhões. Em 2008 ocupou o primeiro lugar na lista da Forbes das pessoas mais ricas do mundo. Infância e adolescência Warren Edward Buffett nasceu em Omaha, Nebraska, Estados Unidos. Segundo dos três filhos de Leila e Howard Buffett, um corretor da bolsa e membro do Congresso dos Estados Unidos. Desde cedo Warren já demonstrava interesse por investimentos e negócios. Ainda criança virou entregador de jornais e batia de porta em porta para vender balas e Coca-Cola. Em 1944, na sua primeira declaração fiscal, declarou sua bicicleta e seu relógio como itens indispensáveis para a realização de seu trabalho e conseguiu uma dedução de US$ 35.  Com 15 anos, usou parte do dinheiro da venda de jornais para, junto com um amigo da escola, comprar uma máquina de pinball e colocá-la em uma barbearia local.  Logo, mais estabelecimentos também teriam as máquinas. O negócio que começou com apenas US$ 25, foi vendido no mesmo ano por US$ 1.200. Seu interesse pela bolsa de valores começou cedo. Adquiriu suas primeiras ações com 10 anos de idade ao visitar o New York Stock Exchange em uma viagem a Nova Iorque. No final da adolescência Buffett já tinha cumulado US$ 9.800, o equivalente a mais de US$ 100 mil em valores corrigidos.  Vida adulta Em 1950, aos 19 anos, Warren Buffett se tornou bacharel em economia pela Universidade Nebraska-Lincoln. No ano seguinte, se tornou mestre em Economia pela Columbia Business School. Lá, foi conheceu Benjamin Graham, chamado de pai do value investing. A influência do professor foi fundamental para sua estratégia de investimento de adquirir ações de empresas boas que estejam abaixo do seu valor de mercado. Não é a toa que Warren Buffett é tido como o maior investidor de todos os tempos. Quando assumiu o controle da Berkshire Hathaway, antiga fábrica têxtil, as ações da empresa podiam ser compradas por menos de US$ 10. Atualmente, uma única ação custa quase US$ 100 mil. Uma assombrosa valorização de 1.000.000% em quarenta anos. Apesar de toda sua fortuna, Warren Buffett é um homem de hábitos simples. Ele vive em Omaha na mesma casa que comprou em 1958 e dirige seu próprio carro, um Cadillac DTS. Nome Completo: Warren Edward Buffett Data de nascimento:  30 de agosto de 1930 Nacionalidade: americano Fortuna: US$ 87,1 bilhões Ocupações: Investidor, CEO da Bershire Hathaway e filantropo Banner will be placed here
Como Warren Buffett Ficou Rico?
Grande parte do patrimônio de Warren Buffett vem de sua atuação como presidente e principal acionista da Berkshire Hathaway, empresa de investimentos fundada por ele na década de 60. À frente da Berkshire, bate consistentemente os índices S&P 500 e Dow Jones, aplicando os conceitos de value investing para multiplicar seu capital. Antes da Berkshire, logo após concluir seus estudos, trabalhou como corretor de investimentos por três anos. Em 1954, foi contratado para trabalhar na Graham-Newman, a empresa de gestão de investimentos do seu mentor, Benjamin Graham. Dois anos depois, decidiu voltar para sua cidade natal e iniciar seu próprio negócio, a Buffett Partnership Ltda. O negócio deu certo e em 1962, com 32 anos, tornou-se milionário. Foi nessa mesma época que Buffett viu nos papéis da Berkshire uma oportunidade de investimento. A companhia que hoje é uma holding de US$ 500 bilhões, era uma falida empresa do setor têxtil. Naquela época, a estratégia de investimento utilizada por Warren Buffett era chamada de “Guimbas de Charuto”. Com ela, buscava identificar empresas que estavam em dificuldades, mas ainda era possível dar um “último trago”. No caso da Berkshire era a recompra de ações. Buffett tinha negociado verbalmente com o então presidente da Berkshire a venda de seus papéis ao preço de US$ 11,50 por ação. No entanto, na hora, a companhia ofereceu somente US$ 11,375. Contrariando sua linha de investimentos, passou a comprar mais ações até assumir o controle da empresa em 1969. Buffett então decidiu encerrar a sociedade na Buffett Partnership e focar na Berkshire Hathaway. Como CEO, diversificou os negócios a empresa. Passou a vender seguros, abandonou o setor têxtil e começou a adquirir participações de grandes empresas. No portfólio da companhia, entraram nomes como Wells Fargo, Bank of America, Visa, Mastercard, Moody’s, Coca-Cola, Kraft-Heinz, Johnson & Johnson, Delta Airlines, American Airlines e General Motors. Atualmente a Berkshire Hathaway é a quinta maior empresa listada no índice S&P 500, com valor de mercado superior a US$ 500 bilhões. Ficando atrás apenas das empresas da Microsoft, Apple, Amazon e Facebook.
Onde Warren Buffett Investe
Ao longo das décadas de investimento na bolsa de valores, Warren Buffett acumula participações em gigantes como Coca-Cola, Kraft-Heinz, Visa e Apple. Por diversas vezes o megainvestidor age no sentido oposto ao mercado. Afirmando ser cauteloso quando os outros são gananciosos, e ganancioso quando os outros estão cautelosos. Uma prova disso foram seus movimentos contrários foi durante a crise de 2008.  Enquanto diversas gestoras tiveram perdas vendendo ações a preços baixos, Buffett aproveitou para investir. Uma das estratégias de investimento de Warren Buffett é justamente essa, comprar na baixa e vender na alta. Assim, consegue verdadeiras barganhas da bolsa. Prova disso foi sua aposta na American Express. Na época, investiu na companhia após sua perda de 50% do valor de mercado. Mas reconheceu o potencial da empresa ao observar que as pessoas estavam começando a usar cartões de crédito em transações diárias. Principais participações acionárias da Berkshire Hathaway: Wells Fargo;Kraft Heinz;IBM;The Coca Cola Company;Bank of America;American Express;Apple;Phillips 66;U.S. Bancorp;Delta Airlines. Detém também participações acionárias menores em outras empresas, tais como: Southwest Airlines, Goldman Sachs, General Motors, DaVita Healthcare, American Airlines, Visa, Monsanto, Liberty Global, Mastercard Inc e Johnson & Johnson.
Estratégia de Investimentos de Warren Buffett
A estratégia de investimento usada pelo maior investidor de todos os tempos é a filosofia do Value Investing. Esse método consiste comprar ações de boas empresas, com expectativas de lucro, mas que por alguma razão, estão abaixo do preço de mercado. Para isso, ele se utiliza de indicadores da análise fundamentalista.  Seus investimentos estão focados no longo prazo e se utilizam do poder dos juros compostos para colher os benefícios. Um fato que evidencia sua estratégia de longo prazo é que 99% da sua fortuna foi acumulada após os 50 anos. Veja os principais pontos da estratégia de Warren Buffett que você também pode aplicar nos seus investimentos: Pensamento a longo prazo Warren Buffett é um dos maiores entusiastas da estratégia do “Buy and Hold”. Essa estratégia de investimentos consiste em adquirir ações de boas empresas e manter os papéis por tempo indeterminado enquanto estiverem boas. A ideia é que você acompanhe o crescimento da empresa e também consiga se aproveitar dos juros compostos no longo prazo. Foque na qualidade Na sua estratégia de investimento, um dos principais focos é a qualidade das empresas. Para escolher as empresas, Buffett utiliza de características, como: Vantagens competitivas duráveis;Administração competente; São empresas lucrativas;Forte geração de caixa;Dívida controlada;Margens altas;Alta rentabilidade. Mantenha a simplicidade Para Warren Buffett, as estratégias bem sucedidas não precisam ser complexas. O mais importante ao comprar uma ação é a qualidade do ativo, o preço e a diversificação de sua carteira. Valuation atrativo Warren Buffett procura comprar boas ações e que estão com o seu preço abaixo do seu valor intrínseco, ou seja, com uma boa margem de segurança. Guarde dinheiro para as oportunidades É preciso sempre ter dinheiro em caixa para aproveitar as oportunidades da bolsa. Portanto, guarde sempre parte do dinheiro para quando encontrar ações de empresas excelentes a bons preços.
Livros de Warren Buffett
Existem diversos livros que falam a respeito dos ensinamentos de Buffett para o mercado de ações. Apesar de não refletirem 100% as ideias de Buffett, são escritos com base nas suas reflexões e ajudam o investidor que busca conhecimento e inspiração. Veja alguns dos melhores livros a respeito de Warren Buffett: O Jeito Warren Buffett de Investir O livro escrito por Robert Hagstrom  apresenta 12 princípios que orientam a filosofia de investimentos de Buffett. Analisa alguns casos de investimento realizados pelo megainvestidor, a importância de investir em negócios que o investidor compreende, ignorar o comportamento volátil do mercado, entre outras lições. A Bola de Neve: Warren Buffett e o negócio da vida Apesar de nunca ter escrito um livro de memórias, o “Oráculo de Omaha”, Warren Buffett, autorizou a escritora Alice Schroeder, a escrever sobre sua vida, opiniões, lutas e triunfos. Warren Buffett – Lições do Maior de Todos os Investidores Escrito por Janet Lowe, o livro contém frases curtas de Warren Buffett que promovem reflexões e ensinamentos sobre a vida, amigos, família, trabalho, gestão de empresas e investimentos.
Frases de Warren Buffett
Parece haver uma característica humana perversa que gosta de fazer as coisas mais fáceis difíceis. O investimento em ações não é tão complexo quanto parece. Ao contrário do que muitos possam imaginar, os modelos de investimento de Warren Buffett são simples e podem ser utilizados por investidores de todos os níveis. Preço é o que você paga. Valor é o que você ganha. Buffett busca ações de empresas que estejam comercializadas a um preço baixo, mas que tenham bons valores para lucrar no longo prazo. O tempo é amigo dos negócios excelentes e inimigo dos negócios medíocres. Warren Buffett tem visão de longo prazo. Sabe que ao adquirir ações de boas empresas com bons fundamentos, o tempo será seu aliado. Esses negócios costumam crescer e gerar bons resultados e retorno aos seus acionistas. Regra número 1: não perca dinheiro. Regra número 2: não esqueça a regra número 1. O grande investidor deve evitar erros. Se eles acontecerem, deve aprender com eles para que não os repita no futuro. Alguém está sentado nas sombras hoje, pois alguém plantou uma árvore muito tempo atrás. Essa frase diz muito da sua mentalidade de longo prazo e na paciência para alcançar os resultados esperados. Risco vem de você não saber o que está fazendo. Todos os investimentos possuem riscos. Uns mais, outros menos. Mas se você sabe quais são esses riscos, fica mais fácil contorná-los.
Conclusão
Warren Buffett  tem um universo de ensinamentos a nos passar. Todos aqueles que buscam inspirações, devem conhecer um pouco mais da sua história e estratégias de investimento. O maior investidor da história e CEO da Berkshire Hathaway, não teme a volatilidade do mercado e sabe que irá crescer no longo prazo. Mas do que isso, ele aproveita os momentos de baixa para adquirir ações de boas empresas. Discípulo de Graham, Warren Buffett investe na bolsa de valores através do método do Value Investing. Assim, busca empresas que estão sendo negociadas abaixo de seu valor e faz análises cuidadosas da gestão, mercado e resultados da companhia. Seu objetivo é ficar com os papéis na carteira por décadas e costuma manter seus investimentos em ambientes que domina. Dedicado à leitura, passa parte do tempo lendo jornais, relatórios e balanços de empresas. Definitivamente, Warren Buffett é um investidor, e não um especulador. Conheça outros Grandes Investidores de Sucesso e Suas Estratégias Vencedoras. Read the full article
0 notes
gordonwilliamsweb · 4 years ago
Text
Dialysis Industry Spends Millions, Emerges as Power Player in California Politics
SACRAMENTO — The nation’s dialysis industry has poured $233 million into California campaigns over the past four years, establishing its leading companies as a formidable political force eager to protect their bottom line and influence state policy.
Tumblr media
This story also ran on Los Angeles Times. It can be republished for free.
Most of the money the industry spent from Jan. 1, 2017, through Nov. 30, 2020, funded the defeat of two union-backed ballot measures that would have regulated dialysis clinics — and eaten into their profits. But the companies and their trade association also stepped up their offense, dedicating about $16.4 million to lobbying and political contributions during the same period, a California Healthline analysis of state campaign finance records shows.
Nearly every member of the legislature, Democratic Gov. Gavin Newsom and his predecessor, former Gov. Jerry Brown, the Democratic and Republican parties, and dozens of political campaigns — including some local school board and city council races — received a contribution from a dialysis company.
“These are very large, very profitable companies,” said Mark Stephens, founder of Prima Health Analytics, a health economics research and consulting firm. “They have a lot to lose. The fear would be that if some of this stuff passed in California, the union would certainly try to get similar measures on the ballot or in the legislatures in other states. The stakes are higher than just California for them.”
Staking Ground in Sacramento
California has about 600 dialysis clinics, which are visited by an estimated 80,000 patients each month, typically three times a week. At the clinics, patients are hooked up to machines that filter toxins and remove excess fluid from their blood because their kidneys can no longer do the job.
Medicare, which covers most dialysis patients, pays a base rate of $239.33 for each dialysis treatment.
DaVita and Fresenius Medical Care North America are the largest dialysis providers in the state and country, operating roughly 80% of clinics nationwide. Last year, DaVita reported $811 million in net income, on revenue of $11.4 billion. Fresenius posted $2 billion in operating income on revenue of $13.6 billion.
DaVita was responsible for about $143 million — or more than three-fifths — of the political spending in the past four years, and Fresenius gave about $68 million.
Until four years ago, the dialysis industry’s political spending was relatively modest compared with that of the hospital, physician and other health care associations so well known in Sacramento. In those days, dialysis lobbyists focused on regulatory issues and health care reimbursement rates, and companies gave minimal campaign contributions.
The industry’s transformation into one of the biggest spenders in California politics began in 2017, the first of four years in which it faced ballot or legislative threats. In 2017, a Democratic lawmaker introduced a bill that would have set strict staff ratios at dialysis clinics. The bill, SB-349, which failed, had faced opposition from the California Hospital Association, the California Chamber of Commerce and the dialysis industry.
The SEIU-United Healthcare Workers West union (SEIU-UHW) followed the next year with Proposition 8, a ballot initiative that would have capped industry profits.
DaVita and Fresenius were forced to defend their huge profits and allegations of subpar patient care, turning the competitors into allies — at least in politics.
The industry spent $111 million to successfully defeat the measure, breaking the record for spending by one side on an initiative.
“I think it’s very natural for these private chains to spend millions to make billions of profits,” said Ryan McDevitt, associate professor of economics at Duke University. “They’re lobbying to protect their profits.”
Last year, the industry fought AB-290, a bill that aimed to stop a billing practice dialysis companies use to get higher insurance reimbursements for some low-income patients. But the legislature wasn’t swayed, and Newsom signed the bill into law, which is now tied up in federal court.
And this year, the industry spent $105 million to block Proposition 23, which would have required every clinic have a physician on site and institute other patient safety protocols.
Kent Thiry, the former chairman and CEO of DaVita, said the industry had no choice but to spend heavily to defeat the ballot measures, which he said would have increased costs and harmed patient care.
“When someone does that, you have to use some of your money to defend yourself, your patients and your teammates,” Thiry said in an interview with KHN, which publishes California Healthline. “It forces companies to allocate precious resources to do something that never should have been brought up to start with.”
In an emailed statement, DaVita said it would continue to work to “educate lawmakers and defend against policy measures that are harmful to our patients.” Fresenius also defended its advocacy, saying the company needs to protect itself against special interests intent on abusing the political system. The company will “continue to support legislation that improves access to quality care and improves patient outcomes,” said Brad Puffer, a company spokesperson.
By comparison, SEIU-UHW, which sponsored the ballot measures, spent about $25 million to advocate for the initiatives, and $7.8 million on lobbying and political contributions. The union lobbies lawmakers on a wide array of health care issues
“They’ve got tons of money. We understand that,” said Dave Regan, the union’s president. “We’ve seen them spend a quarter of a billion dollars in a very short period of time. I hope they’re prepared to spend another quarter of a billion dollars, because we’re not going to go away until there’s legitimate commonsense reforms to this industry.”
From Defense to Offense
While most of dialysis companies’ political spending in California has been used to defeat ballot measures, several of the largest companies also dedicated about $16.4 million to lobbying and political contributions over the past four years.
The companies and their trade association, the California Dialysis Council, put almost three-fourths of that — nearly $12 million — into hiring veteran lobbyists to advocate for dialysis companies when lawmakers consider legislation that could affect the industry.
For instance, when Newsom took office in 2019, both DaVita and Fresenius added Axiom Advisors to their lobbying teams, paying it $737,500 since then. One of the firm’s partners is Newsom’s longtime friend Jason Kinney, whose close relationship with the governor was highlighted by the recent French Laundry dinner fiasco. Newsom came under intense criticism for attending the early November dinner at the exclusive restaurant, held to celebrate Kinney’s birthday, because he and his administration were asking Californians not to gather.
The industry has also given at least $4.6 million in contributions to political candidates and committees, both directly and to entities on behalf of a lawmaker or candidate.
All but five state senators and Assembly members who served during the 2019-20 legislative session received a direct contribution from at least one of the companies or the California Dialysis Council.
Most of the donations to individuals went to state lawmakers, but DaVita dipped into local races, too. For instance, it contributed $10,000 to a Glendale city council candidate in February, $7,700 to an El Monte school board candidate in October and $3,500 to a Signal Hill city council candidate last year.
Dialysis companies also gave to the state Democratic and Republican parties.
“They’re spreading it out. They’re doing the full gambit,” said Bob Stern, former general counsel for the California Fair Political Practices Commission, which enforces state political campaign and lobbying laws.
Legal Loopholes
State law limits how much a company or person can give to a political candidate in an election, but there are legal loopholes that allow individuals and corporate interests to give more. The dialysis industry has taken advantage of them.
Under state campaign finance rules, lawmakers can accept only $4,700 from any one person or company per election.
But some lawmakers operate “ballot measure committees” so they can accept unlimited contributions. These committees are supposed to advocate for a ballot measure, but lawmakers often use them to pay for political consultants and marketing, and to contribute to state and local initiatives they support. Candidates can also get unlimited help from donors who independently pay for campaign costs, such as mailings and digital campaign ads.
For instance, DaVita chipped in $93,505 to help pay for a direct mail campaign on behalf of state Sen. Steve Glazer (D-Orinda) in this year’s primary election. Glazer also received $55,600 from DaVita, Fresenius and the California Dialysis Council in contributions to himself and his ballot committee, Citizens for a Better California.
In some cases, lawmakers such as Glazer who netted some of the biggest contributions from dialysis companies voted with the industry. That was the case last year when the legislature approved AB-290, the bill limiting the dialysis billing practice.
Glazer voted no, as did Assembly member Adam Gray (D-Merced), whose Valley Solutions ballot measure committee had received $112,500 from DaVita and Fresenius since 2017. Gray also received $36,900 in direct contributions from Fresenius, DaVita and U.S. Renal Care.
Gray issued a statement saying campaign contributions play “zero role” in how he represents his district. Glazer did not respond to a request for comment.
Targeting Legislative Adversaries
Assembly member Reggie Jones-Sawyer’s 84-year-old mother is on dialysis. The Los Angeles Democrat and SEIU-UHW member has called for improved staffing ratios at dialysis clinics and has voted repeatedly to regulate them.
DaVita wrote a $249,000 check in October to a political committee supporting Jones-Sawyer’s opponent, Efren Martinez, another Democrat, but one the industry considered more friendly. DaVita followed up with a $15,000 check the week before the election.
Jones-Sawyer, who won the race, said he’s frustrated dialysis companies aren’t willing to make changes to improve patient safety on their own, saying it would cost them far less than the nearly quarter-billion dollars they have spent on political contributions. So for now, he said, he will continue to push to improve conditions at dialysis clinics from the Capitol, despite the industry’s growing political clout.
“I think dialysis is saying, ‘Look, we can be the 800-pound gorilla now,’” Sawyer said. “It’s not just influence for a day; it’s longevity.”
Rae Ellen Bichell and Elizabeth Lucas of KHN contributed to this report.
Methodology
How California Healthline compiled data about dialysis companies’ political spending
Among the ways dialysis companies exert influence on the political process is by contributing money to campaigns; hiring lobbyists; and paying for advertising and marketing on behalf of candidates.
Opposition to ballot measures: Using the California secretary of state’s website, California Healthline downloaded the contributions made by DaVita, Fresenius Medical Care North America, U.S. Renal Care, Satellite Healthcare, Dialysis Clinic Inc. and American Renal Management to the campaign committees formed to defeat Propositions 8 and 23. This includes some non-monetary contributions.
Lobbying: We created a spreadsheet of expenses reported on lobbying disclosure forms, also available on the secretary of state’s website, by DaVita, Fresenius, U.S. Renal Care, Satellite Healthcare and the California Dialysis Council. We found details about how much the industry paid lobbying firms, what agencies it lobbied and which bills it tracked.
Political contributions: DaVita, Fresenius, U.S. Renal Care and the California Dialysis Council made direct contributions to more than 100 candidates, which we compiled from the secretary of state’s website. DaVita and Fresenius made other contributions, often large, to Democratic and Republican committees, and ballot measure committees led by lawmakers. The two companies also made contributions known as “independent expenditures�� that benefited candidates’ campaigns and “behested payments,” which are donations to nonprofit organizations and charities in lawmakers’ names. Behested payments are disclosed on the California Fair Political Practices Commission website.
The SEIU-United Health Care West union uses two political committees for its giving. Its PAC contributes mostly to lawmakers and county and state Democratic parties while its Issues Committee gives to local hospital ballot measures. We did not tally spending for local hospital ballot measures for this story, but we did include contributions made by the Issues Committee to the California Democratic Party, which helps state lawmakers.
This story was produced by KHN, which publishes California Healthline, an editorially independent service of the California Health Care Foundation.
Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.
USE OUR CONTENT
This story can be republished for free (details).
Dialysis Industry Spends Millions, Emerges as Power Player in California Politics published first on https://nootropicspowdersupplier.tumblr.com/
0 notes
stephenmccull · 4 years ago
Text
Dialysis Industry Spends Millions, Emerges as Power Player in California Politics
SACRAMENTO — The nation’s dialysis industry has poured $233 million into California campaigns over the past four years, establishing its leading companies as a formidable political force eager to protect their bottom line and influence state policy.
Tumblr media
This story also ran on Los Angeles Times. It can be republished for free.
Most of the money the industry spent from Jan. 1, 2017, through Nov. 30, 2020, funded the defeat of two union-backed ballot measures that would have regulated dialysis clinics — and eaten into their profits. But the companies and their trade association also stepped up their offense, dedicating about $16.4 million to lobbying and political contributions during the same period, a California Healthline analysis of state campaign finance records shows.
Nearly every member of the legislature, Democratic Gov. Gavin Newsom and his predecessor, former Gov. Jerry Brown, the Democratic and Republican parties, and dozens of political campaigns — including some local school board and city council races — received a contribution from a dialysis company.
“These are very large, very profitable companies,” said Mark Stephens, founder of Prima Health Analytics, a health economics research and consulting firm. “They have a lot to lose. The fear would be that if some of this stuff passed in California, the union would certainly try to get similar measures on the ballot or in the legislatures in other states. The stakes are higher than just California for them.”
Staking Ground in Sacramento
California has about 600 dialysis clinics, which are visited by an estimated 80,000 patients each month, typically three times a week. At the clinics, patients are hooked up to machines that filter toxins and remove excess fluid from their blood because their kidneys can no longer do the job.
Medicare, which covers most dialysis patients, pays a base rate of $239.33 for each dialysis treatment.
DaVita and Fresenius Medical Care North America are the largest dialysis providers in the state and country, operating roughly 80% of clinics nationwide. Last year, DaVita reported $811 million in net income, on revenue of $11.4 billion. Fresenius posted $2 billion in operating income on revenue of $13.6 billion.
DaVita was responsible for about $143 million — or more than three-fifths — of the political spending in the past four years, and Fresenius gave about $68 million.
Until four years ago, the dialysis industry’s political spending was relatively modest compared with that of the hospital, physician and other health care associations so well known in Sacramento. In those days, dialysis lobbyists focused on regulatory issues and health care reimbursement rates, and companies gave minimal campaign contributions.
The industry’s transformation into one of the biggest spenders in California politics began in 2017, the first of four years in which it faced ballot or legislative threats. In 2017, a Democratic lawmaker introduced a bill that would have set strict staff ratios at dialysis clinics. The bill, SB-349, which failed, had faced opposition from the California Hospital Association, the California Chamber of Commerce and the dialysis industry.
The SEIU-United Healthcare Workers West union (SEIU-UHW) followed the next year with Proposition 8, a ballot initiative that would have capped industry profits.
DaVita and Fresenius were forced to defend their huge profits and allegations of subpar patient care, turning the competitors into allies — at least in politics.
The industry spent $111 million to successfully defeat the measure, breaking the record for spending by one side on an initiative.
“I think it’s very natural for these private chains to spend millions to make billions of profits,” said Ryan McDevitt, associate professor of economics at Duke University. “They’re lobbying to protect their profits.”
Last year, the industry fought AB-290, a bill that aimed to stop a billing practice dialysis companies use to get higher insurance reimbursements for some low-income patients. But the legislature wasn’t swayed, and Newsom signed the bill into law, which is now tied up in federal court.
And this year, the industry spent $105 million to block Proposition 23, which would have required every clinic have a physician on site and institute other patient safety protocols.
Kent Thiry, the former chairman and CEO of DaVita, said the industry had no choice but to spend heavily to defeat the ballot measures, which he said would have increased costs and harmed patient care.
“When someone does that, you have to use some of your money to defend yourself, your patients and your teammates,” Thiry said in an interview with KHN, which publishes California Healthline. “It forces companies to allocate precious resources to do something that never should have been brought up to start with.”
In an emailed statement, DaVita said it would continue to work to “educate lawmakers and defend against policy measures that are harmful to our patients.” Fresenius also defended its advocacy, saying the company needs to protect itself against special interests intent on abusing the political system. The company will “continue to support legislation that improves access to quality care and improves patient outcomes,” said Brad Puffer, a company spokesperson.
By comparison, SEIU-UHW, which sponsored the ballot measures, spent about $25 million to advocate for the initiatives, and $7.8 million on lobbying and political contributions. The union lobbies lawmakers on a wide array of health care issues
“They’ve got tons of money. We understand that,” said Dave Regan, the union’s president. “We’ve seen them spend a quarter of a billion dollars in a very short period of time. I hope they’re prepared to spend another quarter of a billion dollars, because we’re not going to go away until there’s legitimate commonsense reforms to this industry.”
From Defense to Offense
While most of dialysis companies’ political spending in California has been used to defeat ballot measures, several of the largest companies also dedicated about $16.4 million to lobbying and political contributions over the past four years.
The companies and their trade association, the California Dialysis Council, put almost three-fourths of that — nearly $12 million — into hiring veteran lobbyists to advocate for dialysis companies when lawmakers consider legislation that could affect the industry.
For instance, when Newsom took office in 2019, both DaVita and Fresenius added Axiom Advisors to their lobbying teams, paying it $737,500 since then. One of the firm’s partners is Newsom’s longtime friend Jason Kinney, whose close relationship with the governor was highlighted by the recent French Laundry dinner fiasco. Newsom came under intense criticism for attending the early November dinner at the exclusive restaurant, held to celebrate Kinney’s birthday, because he and his administration were asking Californians not to gather.
The industry has also given at least $4.6 million in contributions to political candidates and committees, both directly and to entities on behalf of a lawmaker or candidate.
All but five state senators and Assembly members who served during the 2019-20 legislative session received a direct contribution from at least one of the companies or the California Dialysis Council.
Most of the donations to individuals went to state lawmakers, but DaVita dipped into local races, too. For instance, it contributed $10,000 to a Glendale city council candidate in February, $7,700 to an El Monte school board candidate in October and $3,500 to a Signal Hill city council candidate last year.
Dialysis companies also gave to the state Democratic and Republican parties.
“They’re spreading it out. They’re doing the full gambit,” said Bob Stern, former general counsel for the California Fair Political Practices Commission, which enforces state political campaign and lobbying laws.
Legal Loopholes
State law limits how much a company or person can give to a political candidate in an election, but there are legal loopholes that allow individuals and corporate interests to give more. The dialysis industry has taken advantage of them.
Under state campaign finance rules, lawmakers can accept only $4,700 from any one person or company per election.
But some lawmakers operate “ballot measure committees” so they can accept unlimited contributions. These committees are supposed to advocate for a ballot measure, but lawmakers often use them to pay for political consultants and marketing, and to contribute to state and local initiatives they support. Candidates can also get unlimited help from donors who independently pay for campaign costs, such as mailings and digital campaign ads.
For instance, DaVita chipped in $93,505 to help pay for a direct mail campaign on behalf of state Sen. Steve Glazer (D-Orinda) in this year’s primary election. Glazer also received $55,600 from DaVita, Fresenius and the California Dialysis Council in contributions to himself and his ballot committee, Citizens for a Better California.
In some cases, lawmakers such as Glazer who netted some of the biggest contributions from dialysis companies voted with the industry. That was the case last year when the legislature approved AB-290, the bill limiting the dialysis billing practice.
Glazer voted no, as did Assembly member Adam Gray (D-Merced), whose Valley Solutions ballot measure committee had received $112,500 from DaVita and Fresenius since 2017. Gray also received $36,900 in direct contributions from Fresenius, DaVita and U.S. Renal Care.
Gray issued a statement saying campaign contributions play “zero role” in how he represents his district. Glazer did not respond to a request for comment.
Targeting Legislative Adversaries
Assembly member Reggie Jones-Sawyer’s 84-year-old mother is on dialysis. The Los Angeles Democrat and SEIU-UHW member has called for improved staffing ratios at dialysis clinics and has voted repeatedly to regulate them.
DaVita wrote a $249,000 check in October to a political committee supporting Jones-Sawyer’s opponent, Efren Martinez, another Democrat, but one the industry considered more friendly. DaVita followed up with a $15,000 check the week before the election.
Jones-Sawyer, who won the race, said he’s frustrated dialysis companies aren’t willing to make changes to improve patient safety on their own, saying it would cost them far less than the nearly quarter-billion dollars they have spent on political contributions. So for now, he said, he will continue to push to improve conditions at dialysis clinics from the Capitol, despite the industry’s growing political clout.
“I think dialysis is saying, ‘Look, we can be the 800-pound gorilla now,’” Sawyer said. “It’s not just influence for a day; it’s longevity.”
Rae Ellen Bichell and Elizabeth Lucas of KHN contributed to this report.
Methodology
How California Healthline compiled data about dialysis companies’ political spending
Among the ways dialysis companies exert influence on the political process is by contributing money to campaigns; hiring lobbyists; and paying for advertising and marketing on behalf of candidates.
Opposition to ballot measures: Using the California secretary of state’s website, California Healthline downloaded the contributions made by DaVita, Fresenius Medical Care North America, U.S. Renal Care, Satellite Healthcare, Dialysis Clinic Inc. and American Renal Management to the campaign committees formed to defeat Propositions 8 and 23. This includes some non-monetary contributions.
Lobbying: We created a spreadsheet of expenses reported on lobbying disclosure forms, also available on the secretary of state’s website, by DaVita, Fresenius, U.S. Renal Care, Satellite Healthcare and the California Dialysis Council. We found details about how much the industry paid lobbying firms, what agencies it lobbied and which bills it tracked.
Political contributions: DaVita, Fresenius, U.S. Renal Care and the California Dialysis Council made direct contributions to more than 100 candidates, which we compiled from the secretary of state’s website. DaVita and Fresenius made other contributions, often large, to Democratic and Republican committees, and ballot measure committees led by lawmakers. The two companies also made contributions known as “independent expenditures” that benefited candidates’ campaigns and “behested payments,” which are donations to nonprofit organizations and charities in lawmakers’ names. Behested payments are disclosed on the California Fair Political Practices Commission website.
The SEIU-United Health Care West union uses two political committees for its giving. Its PAC contributes mostly to lawmakers and county and state Democratic parties while its Issues Committee gives to local hospital ballot measures. We did not tally spending for local hospital ballot measures for this story, but we did include contributions made by the Issues Committee to the California Democratic Party, which helps state lawmakers.
This story was produced by KHN, which publishes California Healthline, an editorially independent service of the California Health Care Foundation.
Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.
USE OUR CONTENT
This story can be republished for free (details).
Dialysis Industry Spends Millions, Emerges as Power Player in California Politics published first on https://smartdrinkingweb.weebly.com/
0 notes
olko71 · 5 years ago
Text
New Post has been published on All about business online
New Post has been published on http://yaroreviews.info/2019/11/wall-st-ends-near-flat-healthcare-shares-gain-but-trade-deal-delay-weighs
Wall St. ends near flat; healthcare shares gain but trade deal delay weighs
NEW YORK (Reuters) – U.S. stocks ended little changed on Wednesday as a report the U.S.-China trade deal could be delayed until December was offset by gains in healthcare shares.
The Nasdaq broke a three-day string of record closing highs, & the Dow barely snapped its two-day run of record highs.
A senior official of the Trump administration told Reuters a assembly between U.S. President Donald Trump & Chinese President Xi Jinping to sign a long-awaited interim trade deal could be delayed until December, as discussions continue over terms & a venue.
That renewed worries over how long the trade war may continue & caused stocks to trade lower briefly.
“The huge headline was Reuters reporting that the signing of ‘phase one’ would potentially be pushed into December. The market sold off on that yet nothing major, & right now investors are in a holding pattern, waiting to see whether we set new highs & can punch through them,” said Michael O’Rourke, chief market strategist at JonesTrading in Greenwich, Connecticut.
The Trump administration official said it was still possible the “phase one” agreement would not be reached, yet a deal was more likely than not.
The recent rally to record highs had been fueled by signs of progress in the U.S.-China trade talks along with some upbeat earnings reports.
On Wednesday, Humana Inc (HUM.N) rose 3.5% as the health insurer reported quarterly profit that beat estimates on higher sales of its government-backed Medicare Advantage health plans.
CVS Health Corp (CVS.N) gained 5.4% after the pharmacy chain posted a better-than-expected quarterly profit, boosted by its Aetna health insurance commerce & pharmacy benefit management unit. The S&P health care .SPLRCT was up 0.6%.
The Dow Jones Industrial Average .DJI fell 0.07 points to 27,492.56, the S&P 500 .SPX gained 2.16 points, or 0.07%, to 3,076.78 & the Nasdaq Composite .IXIC dropped 24.05 points, or 0.29%, to 8,410.63.
Also in health care, DaVita (DVA.N) shares jumped 12.9% following its results.
The S&P 500 financials index .SPSY extended recent gains, rising 0.4%, while the S&P 500 energy index .SPNY fell 2.3% following declines in oil prices.
Match Group Inc (MTCH.O) fell 2.5% as the Tinder owner forecast fourth-quarter revenue below estimates in the face of stiff competition from rival online dating services. Its parent firm, IAC/InterActiveCorp (IAC.O), dropped 4.3%.
Slideshow (5 Images)
Declining issues outnumbered advancing ones on the NYSE by a 1.21-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.
The S&P 500 posted 14 new 52-week highs & 2 new lows; the Nasdaq Composite recorded 70 new highs & 68 new lows.
Volume on U.S. exchanges was 7.93 billion shares, compared to the 6.74 billion average for the full session over the final 20 trading days.
Editing by Chris Reese, Jonathan Oatis & David Gregorio
Our Standards:The Thomson Reuters Trust Principles.
0 notes
Text
Hemodialysis Concentrates Market presents strong revenue visibility
This study provides insights about the Hemodialysis Concentrates Market in regards to its uses and benefits. We at Crystal Market Research (CMR) provide updated information that is beneficial in decision making regarding business investments.
Market Highlights and Trend Analysis:
The Hemodialysis Concentrates Market has encountered significant development in the recent years and is anticipated to grow tremendously over the forecast period. Hemodialysis concentrate are available in the form of Solution or Powder. Each one consists of Acidified concentrate powders and Bicarbonate concentrate Powder. Dialysis fluid (dialysate) consists of glucose purified water and electrolytes. The concentration of electrolytes nearly resembles that which takes place in the blood naturally. Dialysis fluid is made as per the individual patient’s requirements to help regulate their electrolyte and acid–base balance and eliminate metabolic waste products.
Topmost Key Players:
Some of the leading players in the market are Diaverum Deutschland GmbH, DaVita, Baxter International, NIKKISO CO LTD, B. Braun Melsungen, Nipro, NxStage and Fresenius Medical Care. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
Market segmentation:
The Hemodialysis Concentrates Market is segmented on the basis of product and application. Based on product the market is segmented into Bicarbonate Concentrates and Acid Concentrates. On the basis of application the market is segmented into Home and Dialysis Centre.
Request Exclusive Sample Copy of Hemodialysis Concentrates Market at: https://www.crystalmarketresearch.com/report-sample/HC06950 .
Regional Outlook and Trend Analysis:
North America held a sizeable share of the overall industry in the hemodialysis concentrate market which was trailed by Asia Pacific, Europe and rest of the world. The Asia-Pacific district is anticipated to rule the market over the gauge time frame particularly in China attributable to the expanding number of patients with renal illnesses, expanding number of dialysis concentrates, rising number of government activities to change and create dialysis offices, expanding awareness among individuals about new dialysis treatment modalities and high number of ESRD patient populace base.
The Hemodialysis Concentrates Market is segmented as follows-
By Product: Acid Concentrates & Bicarbonate Concentrates
By Application: Dialysis Centre & Home
By Region: North America: (U.S., Canada & Mexico), Europe: (Germany, UK, France, Russia, Italy & Rest of Europe), Asia-Pacific: (China, Japan, South Korea, India, Southeast Asia & Rest of Asia-Pacific), South America: (Brazil, Argentina, Columbia, South Africa & Rest of South America) and Middle East and Africa: (Saudi Arabia, UAE, Egypt, Nigeria, South Africa & Rest of MEA)
Drivers and Restraints:
The hemodialysis Concentrates market is expected to develop over the figure time frame and the pattern is anticipated to continue in the following years. An expanding number of end stage chronic disease patients and patient experiencing hypertension and diabetes are the fundamental driving components for the development of hemodialysis Concentrates market.  Rising patterns including expanding venture financing and private investments to help the manufacturing of cutting edge products alongside expanding government spending on healthcare for end stage renal diseases treatment are the potential factors that may fundamentally boost the hemodialysis Concentrates market throughout the following years. Moreover, low inclination by the patients for kidney transplantation combined with the technological progressions to help hemodialysis concentrates is evaluated to fuel the interest for industry.
Make an Enquiry of report for Discount at: https://www.crystalmarketresearch.com/check-discount/HC06950
Major Table of Contents:
Part 1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
Part 2. Executive Summary
2.1. Key Highlights
Part 3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
Part 4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2014-2023)
4.1.2. Canada Market States and Outlook (2014-2023)
4.1.3. Mexico Market States and Outlook (2014-2023)
Part 5. Hemodialysis Concentrates Market, By Product
5.1. Introduction
5.2. Global Hemodialysis Concentrates Sales, Revenue and Market Share by Product (2014-2018)
5.2.1. Global Hemodialysis Concentrates Sales and Sales Share by Product (2014-2018)
5.2.2. Global Hemodialysis Concentrates Revenue and Revenue Share by Product (2014-2018)
5.3. Acid Concentrates
5.3.1. Global Acid Concentrates Sales and Growth Rate (2014-2018)
5.4. Bicarbonate Concentrates
5.4.1. Global Bicarbonate Concentrates Sales and Growth Rate (2014-2018)
…Read Full Table of Contents
(Early buyers will receive 10% customization on this report.)
Place a purchase order of this report at: https://www.crystalmarketresearch.com/checkout/HC06950 .
About Crystal Market Research: Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.
Contact Us: Judy 304 South Jones Blvd, Suite 1896, Las Vegas NV 89107, United States Toll Free: +1-888-213-4282 Email: [email protected]
0 notes
crystalmarketresearch · 6 years ago
Text
Hemodialysis Concentrates Market Opportunity Analysis and Industry Forecast Upto 2023
A research study titled, “Hemodialysis Concentrates Market by product and application - global industry analysis and forecast to 2023”, published by crystal market research. Market Highlights:  The Hemodialysis Concentrates Market has encountered significant development in the recent years and is anticipated to grow tremendously over the forecast period. Hemodialysis concentrate are available in the form of Solution or Powder. Each one consists of Acidified concentrate powders and Bicarbonate concentrate Powder. Dialysis fluid (dialysate) consists of glucose purified water and electrolytes. The concentration of electrolytes nearly resembles that which takes place in the blood naturally. Dialysis fluid is made as per the individual patient’s requirements to help regulate their electrolyte and acid–base balance and eliminate metabolic waste products.
Click To Request A Sample: https://www.crystalmarketresearch.com/report-sample/HC06950
 Hemodialysis Concentrates Market -Segmentation The Hemodialysis Concentrates Market is segmented on the basis of product and application. Based on product the market is segmented into Bicarbonate Concentrates and Acid Concentrates. On the basis of application the market is segmented into Home and Dialysis Centre.
Hemodialysis Concentrates Market - By Region: Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) North America (U.S, Canada, Mexico) Europe (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific) Rest of the World (Brazil, South Africa, Saudi Arabia, Turky, United Arab Emirates, Others Read Premium News from  AB Newswire of http://www.abnewswire.com/pressreleases/International-Digital-Health-Market”at: http://www.abnewswire.com/pressreleases/international-digital-health-market-2018-estimated-to-be-around-usd-382-billion-competitive-key-players-detail-overview-by-key-segments-and-success-ratio-till-2023_228345.html
Competitive Insights: Some of the leading players in the market are Diaverum Deutschland GmbH, DaVita, Baxter International, NIKKISO CO LTD, B. Braun Melsungen, Nipro, NxStage and Fresenius Medical Care. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry. 
Regional Outlook and Trend Analysis: North America held a sizeable share of the overall industry in the hemodialysis concentrate market which was trailed by Asia Pacific, Europe and rest of the world. The Asia-Pacific district is anticipated to rule the market over the gauge time frame particularly in China attributable to the expanding number of patients with renal illnesses, expanding number of dialysis concentrates, rising number of government activities to change and create dialysis offices, expanding awareness among individuals about new dialysis treatment modalities and high number of ESRD patient populace base.
Research Methodology We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Check discount offer for Report click on the link @ https://www.crystalmarketresearch.com/check-discount/HC06950
About Crystal Market Research: Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy. Contact Us: Judy S, 304 South Jones Blvd, Suite 1896, Las Vegas NV 89107, United States Toll Free: +1-888-213-4282 Email: [email protected]
0 notes